Phytocannabinoid Transdermal Formulation for Sustained Skin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transdermal formulations for pain and inflammation treatment are inefficient in delivering phytocannabinoids effectively through the skin, leading to suboptimal therapeutic outcomes.
Innovation Solution
A transdermal formulation comprising phytocannabinoids dispersed in a pharmaceutically acceptable carrier with specific ratios of penetration enhancers, thickening agents, buffering agents, sequestering agents, and preservatives, along with deionized water, which includes microencapsulated cannabidiol, enhances skin penetration and sustained delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional transdermal formulations are used, then the formulation is simple, but the delivery efficiency of phytocannabinoids through the skin is poor
Solution Approach 1:
The patent employs a composite formulation system combining phytocannabinoids with specific penetration enhancers (azones, DMSO, terpenes), thickening agents (carboxymethyl cellulose, xanthan gum), buffering agents (triethanolamine), and preservatives (phenoxyethanol). This multi-component composite approach synergistically enhances skin penetration and sustained delivery of phytocannabinoids while maintaining formulation stability and safety.
Solution Approach 2:
The patent optimizes specific concentration parameters: penetration enhancer at 1-10% w/w, thickening agent at 0.1-5% w/w, buffering agent at 0.1-3% w/w, and preservative at 0.1-2% w/w. These parameter optimizations ensure effective skin penetration and sustained release while maintaining acceptable viscosity, pH balance, and microbial stability.
2Reliability
If higher concentrations of phytocannabinoids are used, then the therapeutic effect is improved, but the skin penetration and delivery efficiency deteriorate
Solution Approach 1:
The patent introduces penetration enhancers as intermediary substances that facilitate the transport of phytocannabinoids through the skin barrier. Azones, DMSO, and terpenes act as carriers that enhance membrane permeability and enable efficient delivery of phytocannabinoids even at therapeutic concentrations, resolving the contradiction between dosage and penetration efficiency.
3Duration of action of moving object
If the formulation is designed for sustained delivery, then the duration of action is improved, but the initial penetration rate decreases
Solution Approach 1:
The patent incorporates thickening agents (carboxymethyl cellulose, xanthan gum) that create a controlled-release matrix, maintaining continuous skin contact and sustained penetration over extended periods. The formulation is designed to provide consistent delivery throughout the duration of application, ensuring both initial penetration and prolonged therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved and sustained delivery of phytocannabinoids, demonstrating increased cannabidiol delivery through the skin over time, providing effective relief for musculoskeletal pain and inflammation.
Implementation Method 1
about 3% w/w to about 30% w/w penetration enhancer
Implementation Method 2
about 0.8% w/w to about 1.3% w/w thickening agent
Implementation Method 3
about 0.25% w/w to about 6% w/w buffering agent
Implementation Method 4
about 0.05% w/w to about 0.08% w/w sequestering agent
Implementation Method 5
about 0.4% w/w to about 0.8% w/w of preservative
Implementation Method 6
the cannabidiol is microencapsulated cannabidiol
Implementation Method 7
demonstrating increased cannabidiol delivery through the skin over time
Data Source
AI summary
Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.